Compare SGC & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGC | DTIL |
|---|---|---|
| Founded | 1920 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.6M | 136.0M |
| IPO Year | 1994 | 2019 |
| Metric | SGC | DTIL |
|---|---|---|
| Price | $10.70 | $7.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $16.00 | ★ $60.00 |
| AVG Volume (30 Days) | 32.4K | ★ 348.8K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.20% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | $566,184,000.00 | ★ $1,070,000,000.00 |
| Revenue This Year | $3.23 | N/A |
| Revenue Next Year | $3.82 | N/A |
| P/E Ratio | $23.33 | ★ N/A |
| Revenue Growth | ★ 0.09 | N/A |
| 52 Week Low | $8.30 | $3.53 |
| 52 Week High | $13.78 | $8.82 |
| Indicator | SGC | DTIL |
|---|---|---|
| Relative Strength Index (RSI) | 61.43 | 69.53 |
| Support Level | $9.79 | $4.50 |
| Resistance Level | $10.84 | $7.59 |
| Average True Range (ATR) | 0.22 | 0.54 |
| MACD | 0.06 | 0.06 |
| Stochastic Oscillator | 84.70 | 89.82 |
Superior Group Of Companies Inc designs apparel products. The company operates through three segments: i) The Branded Products segment, under the brands BAMKO and HPI, produces and sells customized merchandising solutions, promotional products, and branded uniform programs. ii) The Healthcare Apparel segment, under the brands Wink and Fashion Seal Healthcare, manufactures and sells healthcare apparel including scrubs, lab coats, protective apparel, and patient garments. iii) The Contact Centers segment, through The Office Gurus entities, provides outsourced, nearshore, and onshore business process outsourcing (BPO), contact center, and call-center support services to customers in North America. The majority of the company's revenue is derived from the Branded Products segment.
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).